Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (the "Company") on March 24, 2019. The filing discloses the entry into a material definitive agreement for a registered public offering of common stock and reports on other events, including attempted business email compromises.
Key Financial Metrics and Transaction Details
- Offering Proceeds: The Company agreed to sell 1,331,332 shares of common stock at $0.20 per share, generating gross proceeds of approximately $266,266.
- Placement Agent Fees: Ladenburg Thalmann & Co. Inc. will receive a cash fee equal to 8% of gross proceeds, a management fee of 1% of gross proceeds, and reimbursement of $25,000 in expenses.
- Warrant Issuance: The Placement Agent received a warrant to purchase 53,253 shares of Common Stock at an exercise price of $0.25 per share.
- Cash Flow and Liquidity: The filing does not provide current cash balance, debt levels, or operating cash flow figures. The transaction is intended to raise capital.
Material Changes and Other Events
Capital Structure Change: The Company is increasing its outstanding share count by 1,331,332 shares through the offering to Oasis Capital, LLC.
Security Incident: The Company reported several attempted business email compromises in the first quarter of 2019. One incident resulted in a diverted wire payment of approximately $126,000, which was subsequently recovered. The Company states there is no known financial loss at this time, though an investigation into internal controls is ongoing.
Guidance, Outlook, and Risks
- Outlook: The Company expects to file a prospectus supplement for the offering on or about March 25, 2019.
- Risks: The filing highlights the risk of business email compromise and the ongoing review of internal controls. The Placement Agent Warrant and related shares are unregistered and issued under Section 4(a)(2) exemptions.
- Contingencies: The Company is continuing to investigate the impact of the security incident on its financial statements.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting the 9% total cash fees and $25,000 expense reimbursement.
- Confirm the status of the investigation into the $126,000 wire diversion and whether any additional financial losses or regulatory penalties are anticipated.
- Review the attached Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or redemption rights.
- Monitor the filing of the prospectus supplement to confirm the final terms of the offering.